Quebec News Tribune – Lifestyle
Author:
Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
April 23, 2026
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
April 23, 2026
Case Report of Mabwell’s Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
April 21, 2026
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
April 20, 2026
Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
April 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
April 15, 2026
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
April 14, 2026